ERBB2 and triple-negative breast carcinoma: In the training cohort, 224 cases (35.3%) were HR-positive/HER2-negative, 133 cases (20.9%) were HR-positive/HER2-positive, 109 cases (17.2%) were HR-negative/HER2-positive, and 169 cases (26.6%) were triple negative breast cancer (TNBC).